Article
Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.
Future oncology (London, England) - 1 Aug 2022
Goggin Caitriona, Stansfeld Anna, Mahalingam Preethika, Thway Khin, Smith Myles J, Huang Paul, Jones Robin L, Napolitano Andrea
Abstract excerpt
Over the past 20 years, the management of gastrointestinal stromal tumors has acted as an important model in the advancement of molecularly targeted therapies for solid tumors. The success of imatinib has established it as a lasting therapy in the management of early-stage and advanced disease in the first-line setting. Imatinib resistance inevitably develops, resulting in the need for further lines of therapy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.